Aprogen Biologics Inc. (KRX:003060)
694.00
+23.00 (3.43%)
Last updated: Jun 5, 2025
Aprogen Biologics Revenue
Aprogen Biologics had revenue of 16.85B KRW in the quarter ending March 31, 2025, with 7.96% growth. This brings the company's revenue in the last twelve months to 68.62B, down -19.76% year-over-year. In the year 2024, Aprogen Biologics had annual revenue of 67.38B, down -22.88%.
Revenue (ttm)
68.62B
Revenue Growth
-19.76%
P/S Ratio
3.15
Revenue / Employee
182.02M
Employees
377
Market Cap
215.83B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 67.38B | -19.99B | -22.88% |
Dec 31, 2023 | 87.36B | 22.17B | 34.01% |
Dec 31, 2022 | 65.19B | 8.71B | 15.42% |
Dec 31, 2021 | 56.48B | 3.16B | 5.93% |
Dec 31, 2020 | 53.32B | 2.42B | 4.75% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,898.69B |
Celltrion | 3,662.23B |
ALTEOGEN | 151.65B |
Yuhan | 2,114.76B |
SK Biopharmaceuticals | 578.00B |
HLB Co., Ltd. | 74.64B |
PharmaResearch | 392.31B |
LigaChem Biosciences | 146.42B |